Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) Return on Sales: 2018-2023

Historic Return on Sales for Denali Therapeutics (DNLI) over the last 5 years, with Sep 2023 value amounting to -1.23%.

  • Denali Therapeutics' Return on Sales rose 158.00% to -1.23% in Q3 2023 from the same period last year, while for Sep 2023 it was -1.23%, marking a year-over-year increase of 158.00%. This contributed to the annual value of -0.44% for FY2023, which is 257.00% up from last year.
  • According to the latest figures from Q3 2023, Denali Therapeutics' Return on Sales is -1.23%, which was up 0.27% from -1.23% recorded in Q2 2023.
  • Denali Therapeutics' Return on Sales' 5-year high stood at 0.21% during Q4 2020, with a 5-year trough of -9.69% in Q3 2020.
  • In the last 3 years, Denali Therapeutics' Return on Sales had a median value of -2.59% in 2022 and averaged -2.29%.
  • In the last 5 years, Denali Therapeutics' Return on Sales slumped by 924bps in 2020 and then skyrocketed by 977bps in 2021.
  • Over the past 5 years, Denali Therapeutics' Return on Sales (Quarterly) stood at -7.41% in 2019, then surged by 762bps to 0.21% in 2020, then slumped by 735bps to -7.14% in 2021, then soared by 406bps to -3.08% in 2022, then skyrocketed by 158bps to -1.23% in 2023.
  • Its Return on Sales was -1.23% in Q3 2023, compared to -1.23% in Q2 2023 and -3.72% in Q1 2023.